Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Recursion Pharmaceuticals, Inc. or Amarin Corporation plc because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Recursion Pharmaceuticals, Inc. and Amarin Corporation plc compare based on key financial metrics to determine which better meets your investment needs.

About Recursion Pharmaceuticals, Inc. and Amarin Corporation plc

Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-1245, which is in Phase 1/2 clinical trial to treat biomarker-enriched solid tumors and lymphoma; REC-3565 that is in Phase 1/2 for the treatment of relapsed or refractory B-cell malignancies; and REC-4539, a reversible, CNS penetrant, orally bioavailable, and potential best-in-class inhibitor of LSD1 for the treatment of solid tumors and hematology oncology. Its preclinical stage product includes REC-7735 for the treatment of HR+ breast cancer; and REC-102 for the treatment of hypophosphatasia. The company has collaboration and agreement with Roche & Genentech; Sanofi; Bayer AG; Tempus; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. It offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally through wholesalers, selected regional wholesalers, and retail and mail order pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, EPA. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.

Latest Biotechnology and Recursion Pharmaceuticals, Inc., Amarin Corporation plc Stock News

As of April 21, 2026, Recursion Pharmaceuticals, Inc. had a $1.9 billion market capitalization, compared to the Biotechnology median of $280.7 million. Recursion Pharmaceuticals, Inc.’s stock is NA in 2026, NA in the previous five trading days and down 35.46% in the past year.

Currently, Recursion Pharmaceuticals, Inc. does not have a price-earnings ratio. Recursion Pharmaceuticals, Inc.’s trailing 12-month revenue is $74.7 million with a -863.4% net profit margin. Year-over-year quarterly sales growth most recently was 688.9%. Analysts expect adjusted earnings to reach $-0.948 per share for the current fiscal year. Recursion Pharmaceuticals, Inc. does not currently pay a dividend.

Currently, Amarin Corporation plc does not have a price-earnings ratio. Amarin Corporation plc’s trailing 12-month revenue is $213.6 million with a -18.2% net profit margin. Year-over-year quarterly sales growth most recently was -21.0%. Analysts expect adjusted earnings to reach $0.780 per share for the current fiscal year. Amarin Corporation plc does not currently pay a dividend.

How We Compare Recursion Pharmaceuticals, Inc. and Amarin Corporation plc Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Recursion Pharmaceuticals, Inc. and Amarin Corporation plc’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Recursion Pharmaceuticals, Inc. and Amarin Corporation plc Stock Value Grades

Company	Ticker	Value
Recursion Pharmaceuticals, Inc.	RXRX	F
Amarin Corporation plc	AMRN	B

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection.

Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Value Grade derives from a stock’s value score. The Value Score is the percentile rank of the average of the percentile ranks of the price-to-sales ratio, price-earnings ratio, enterprise-value-to-EBITDA (EV/EBITDA) ratio, shareholder yield, price-to-book-value ratio and price-to-free-cash-flow ratio. The score is variable, meaning it can consider all six ratios or, should any of the six ratios not be valid, the remaining ratios that are valid. To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are a good value and so on.

Recursion Pharmaceuticals, Inc. has a Value Score of 11, which is Ultra Expensive. Amarin Corporation plc has a Value Score of 65, which is Value.

The Value Stock Winner: Amarin Corporation plc

As you can clearly see from the Value Grade breakdown above, Amarin Corporation plc is considered to have better value than Recursion Pharmaceuticals, Inc.. For investors who focus solely on a company’s valuation, Amarin Corporation plc could be a good stock to add to their portfolio. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Recursion Pharmaceuticals, Inc. and Amarin Corporation plc’s Quality Grades

Company	Ticker	Quality
Recursion Pharmaceuticals, Inc.	RXRX	D
Amarin Corporation plc	AMRN	C

Like the Value Grade, AAII’s A+ Investor Quality Grade comes from the percentile rank of key metrics. Specifically, the Quality Score is the percentile rank of the average of the percentile ranks of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and the F-Score.

The score is variable, meaning it can consider all eight measures or, should any of the eight measures not be valid, the remaining measures that are valid. To be assigned a Quality Score, stocks must have a valid (non-null) measure and corresponding ranking for at least four of the eight quality measures.

The Quality Score is used to assess the underlying “quality” of a particular stock. A higher-quality stock possesses traits associated with upside potential and reduced downside risk. Backtesting of the Quality Grade shows that stocks with higher grades, on average, outperformed stocks with lower grades over the period of 1998 through 2019.

Stocks receive better grades (higher scores) for having higher scores for the quality subcomponents and worse grades (lower scores) for lower scores for the subcomponents.

Recursion Pharmaceuticals, Inc. has a Quality Score of 25, which is Weak. Amarin Corporation plc has a Quality Score of 50, which is Average.

The Quality Stock Winner: No Clear Winner

Neither Recursion Pharmaceuticals, Inc. or Amarin Corporation plc has a high enough Quality Grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if Recursion Pharmaceuticals, Inc. or Amarin Corporation plc is the better investment when it comes to quality.

Recursion Pharmaceuticals, Inc. and Amarin Corporation plc’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
Recursion Pharmaceuticals, Inc.	RXRX	B
Amarin Corporation plc	AMRN	B

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

Recursion Pharmaceuticals, Inc. has a Earnings Estimate Score of 68, which is Positive. Amarin Corporation plc has a Earnings Estimate Score of 65, which is Positive.

The Earnings Estimate Revisions Grade Winner: It’s a Tie!

Looking at the Earnings Estimate Revisions Grade breakdown above, both Recursion Pharmaceuticals, Inc. and Amarin Corporation plc have a grade of B. For those focusing solely on a company’s estimate revisions, other financial metrics will need to be evaluated to determine whether Recursion Pharmaceuticals, Inc. or Amarin Corporation plc is a better fit.

Other Recursion Pharmaceuticals, Inc. and Amarin Corporation plc Grades

In addition to Quality, Estimate Revisions and Value, A+ Investor also provides grades for Growth and Momentum.

Momentum grades help uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming.

Growth investing builds on the idea that stocks of companies exhibiting strong, consistent and prolonged growth outperform those of slower-growth companies. AAII measures growth through consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Recursion Pharmaceuticals, Inc. and Amarin Corporation plc pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Recursion Pharmaceuticals, Inc. or Amarin Corporation plc Stock?

Overall, Recursion Pharmaceuticals, Inc. stock has a Value Score of 11, Estimate Revisions Score of 68 and Quality Score of 25.

Amarin Corporation plc stock has a Value Score of 65, Estimate Revisions Score of 65 and Quality Score of 50.

Comparing Recursion Pharmaceuticals, Inc. and Amarin Corporation plc’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.